AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06401187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bar overdenture
Description: use of bar attachments as retentive mean of denture
Study NCT06401187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bar overdenture
Description: use of bar attachments as retentive mean of denture
Study NCT06032897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized music listening (IML)
Description: The earphones were placed on individuals in the experimental group to listen to individualized music for 20 minutes. The Individualized music listening (IML) were performed twice a week for four weeks, for a total of eight times.
Study NCT04774003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
Description: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1
Study NCT04774003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1
Study NCT04774003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)
Description: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1
Study NCT05651256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: The solution for injection was prepared immediately before the intervention, by dissolving the vials of BTX, kept refrigerated at 5ºC, in 1 ml of sterile saline solution at room temperature. Eight injection sites were marked, three located in the masseter muscle, two in the lateral pterygoid muscle, one in the temporomandibular joint (TMJ) and two in the temporalis muscle. A 1 cc marked insulin syringe was used for intramuscular injection of the prepared solution, according to the locations and amounts proposed by Kim et al. and Ho et al. with a total dose of 100 U in each patient.distributed at the different injection sites.
Study NCT05510817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multiparametric assessment
Description: neuropsychological assessment, PRO measures, non-conventional MRI metrics
Study NCT04935632 — intervention group
Intervention type: BEHAVIORAL
Intervention: prevention training
Description: Evaluate the impact of hypothermia prevention training on the proportion of patients hypothermic patients in the operating room
Study NCT05229900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-ALPV
Description: Given into the vein (IV; intravenously)
Study NCT05331079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: 20 minutes of cryotherapy on the dominant knee with ice bags
Study NCT04461041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Single oral tablet
Study NCT04461041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet manufactured to mimic empagliflozin 10 mg tablet
Study NCT05665686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relaxation training with device
Description: Relaxation training will be applied with the device.
Study NCT05665686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: An exercise application including home exercise programs will be performed for six weeks.
Study NCT06223763 — intervention group
Intervention type: PROCEDURE
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery is a surgical procedure performed with the goal of reducing the tumor burden in the body. This type of surgery is commonly used in the treatment of certain types of cancers, especially in the context of peritoneal carcinomatosis. During cytoreductive surgery, the surgeon attempts to remove as much visible tumor as possible. This may involve the removal of tumors from specific organs and the elimination of tumor lesions on the surface of intra-abdominal organs.
Study NCT06223763 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: Neoadjuvant chemotherapy refers to chemotherapy administered before the primary treatment in cancer management. The goals include reducing tumor size, treating micrometastases, assessing treatment response, converting inoperable tumors to operable ones, and preserving organs or tissues.
Study NCT06223763 — intervention group
Intervention type: DRUG
Intervention: Adjuvant chemotherapy
Description: Adjuvant chemotherapy is chemotherapy given after the primary treatment, such as surgery or radiation therapy, with the aim of eliminating any remaining cancer cells and reducing the risk of recurrence. It is administered to patients who have undergone the initial treatment to enhance the overall effectiveness of the therapy.
Study NCT04766333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare Worker Focused Outreach
Description: This a focused outreach intervention strategy specifically designed for healthcare workers.
Study NCT04766333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Organization Led Outreach
Description: This is a standard community engaged outreach approach that has traditionally been used in previous research. Analogous to the standard of care for outreach.
Study NCT04201600 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring System (CGMS)
Description: Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.
Study NCT05974553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Justice-Involved Veterans
Description: 16 weeks of Dialectical Behavior Therapy for Justice-Involved Veterans, including weekly 60-minute group therapy and biweekly 30-minute individual case management
Study NCT06487351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The adapted PHBI
Description: The adapted intervention is expected to be an online 60-minute video with an educational part about implicit racial bias, its consequences in healthcare inequalities, how to mitigate it, and seven case scenarios (5 minutes each) to train pharmacy interns on aspects related to cultural competency and how and when to use IBMS to reduce the impact of bias on prescribing PrEP for people of color.
Study NCT05974553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Group Psychotherapy for Justice-Involved Veterans
Description: 16 weeks of clinician-facilitated supportive group psychotherapy for justice-involved Veterans, including weekly 75-minute group psychotherapy (20 hours total intervention). All interventions delivered via telehealth.
Study NCT06487351 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The NIH Implicit Bias course
Description: The NIH Implicit Bias course consists of three modules designed to teach users what bias is, how to recognize it, and how to minimize its impact
Study NCT06637176 — intervention group
Intervention type: DEVICE
Intervention: Laser speckle contrast imaging
Description: LSCI measurements will be taken before and after the formation of the anastomosis, with the surgeon blinded to the measurements to prevent any influence on surgical decision-making. The surgery will be performed as standard-of-care, unaffected by the LSCI measurements.~Following the surgery, the LSCI images will be presented to the surgeon, who will complete a questionnaire assessing whether the LSCI images, if presented perioperatively, would have influenced their decision regarding the location of the anastomotic site. Additionally, the surgeon will be asked if they consider LSCI to be a useful intraoperative tool in general. The surgical case and the series of LSCI images will also be presented to an independent surgeon, who will answer the same set of questions.~The LSCI measurements will be correlated with 30-day complication rates, with a specific focus on anastomotic leakage (AL).~Microcirculation is assessed using LSCI at a wavelength of 785 nm (MoorFLPI-2, Moor Instruments
Study NCT04942197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: use pregnancy management application
Description: Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.
Study NCT04942197 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: use pregnancy management application
Description: Pregnant women who used pregnancy management application, which tells patients what she need to know during pregnancy, when to perform tests, and what precautions to take for your baby.
Study NCT04591015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital: DD-CA
Description: In the DD-CA group, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with educational, motivational and medication adherence messaging that is currently an arm of our parent DD-ME grant with added COVID support messages that provide information addressing identified barriers in Hispanic underserved communities (e.g. obtaining testing supplies and medications, accessing routine medical care, and completing other important diabetes self-management behaviors such as healthful eating, exercise, social distancing, quarantine, and stay-at-home/lockdown guidelines).
Study NCT04591015 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hospital: Usual Care (UC)
Description: In the UC group, participants will not receive the added COVID support messages, both groups will have a referral placed to the Diabetes Transitions Service (DTS) at the time of discharge as part of usual care. Participants will be contacted by a peer health coach following protocol to coordinate care with outpatient health and other community resources.
Study NCT05134818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observer tool
Description: comparison of the efficacy of an observer tool to enhance learning of technical skills of CVC insertion in anesthesiology residents The resident will complete an observer tool each time another resident is observed to insert a CVC on the simulator.
Study NCT05080491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: immuno analysis and neuropsychological tests
Description: A venous blood sample will be taken for assay in immuno-analysis including and for assay in chromatography with mass spectrometry. Patients will participate in computer neuropsychological tests: .~Venous blood collection and the administration : the tubes are transported to the biochemistry laboratory of the University Hospital Center of Nice (CHU Nice) which prepares five aliquots (4 for assays in immuno-analysis including 2 on site, and one for assay in chromatography with mass spectrometry.~Administration of two neuropsychological tests on computer(Attention Network Task and Tower of London).
Study NCT05311865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Club event
Description: Participate in a club event without a mask, indoors, with vaccinated people.
Study NCT05036473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Description: Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
Study NCT05036473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets-matching the active groups.
Study NCT06238401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR246 for injection
Description: 80 mg/vial
Study NCT04969835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVA6000
Description: AVA6000 is a FAP-activated doxorubicin.
Study NCT06340919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sudden Sound Reduction Setting
Description: Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Low, High, or Maximum. Recordings with the different settings will be randomized from trial to trial.
Study NCT05913375 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate defined with electroanatomical mapping (EAM)
Study NCT04908995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC5026 oral tablet
Description: 12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~* Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~* Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2.
Study NCT04908995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period.
Study NCT06047704 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06475469 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling & Chest CT without injection
Description: Anlaysis of the repartition of non-tumorous lymphocytic subpopulation in patients with untreated Chronic Lymphocytic Leukemia (CLL)
Study NCT05838326 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symmetrical high flow nasal cannula (HFNO)
Description: After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.
Study NCT05838326 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Asymmetrical high flow nasal cannula (DUET HFNO)
Description: After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.~A 5-10min 'washout' phase using VM, between different interfaces, will be allowed.
Study NCT05106153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Suvorexant will be administered orally as per assigned treatment sequence.
Study NCT05106153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem will be administered orally as per assigned treatment sequence.
Study NCT05106153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally as per assigned treatment sequence.
Study NCT05106153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally as per assigned treatment sequence.
Study NCT06422182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain 25% (Erector Spinae Plane Block)
Description: Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.
Study NCT06422182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine (Intravenous patient-controlled analgesia)
Description: Patients received intravenous patient-controlled analgesia (IV-PCA) by morphine
Study NCT05922202 — intervention group
Intervention type: OTHER
Intervention: Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months
Description: At 12 and 24 months of follow up, cardiovascular events (including hospital admissions), deaths due to cardiovascular disease, deaths due to all-cause, deaths due to COPD will be recorded in COPD outpatients group.
Study NCT04939857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: The experimental group will be treated with trimetazidine, and the control group will not be intervened
Study NCT05532397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPOP category 1
Description: combination regimens with published data in the setting of gliomas
Study NCT05532397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPOP category 2
Description: combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
Study NCT05527951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eMBC
Description: The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
Study NCT05527951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard MBC
Description: The control intervention group will implement standard MBC using paper and pencil questionnaires.
Study NCT06070428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAC provision at hospital discharge
Description: Patients randomized to receive the intervention will receive two PACs fitted with True HEPA filters.
Study NCT06070428 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control non-intervention; PAC without filter
Description: Patients randomized to the control non-interventional arm will receive two PACs with no filters inserted.
Study NCT05093790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Specified dose on specified days
Study NCT05093790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141
Description: Specified dose on specified days
Study NCT05093790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Specified dose on specified days
Study NCT05304091 — intervention group
Intervention type: OTHER
Intervention: Questionnaire on a smartphone application
Description: Each day, the smartphone application will ask the patient if he or she is having an angioedema attack. It not, the questionnaire will stop. If the patient is having an attack, a series of 5 short questions is asked about the attack characteristics and the events that preceded it.
Study NCT04999254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: Medical treatment will be based on functional treatment and the doctor will prescribe the RICE protocol. For this, the patient will have to :~* place an ice pack on the sprain~* apply sports rest for three weeks~* compress the sprain with a compression stocking when standing in order to prevent phlebitis. In addition, to avoid this complication, the doctor will prescribe an anticoagulant.~* raise the foot with crutches during the day~* elevate the foot at night or when doing an activity in a sitting position, using a cushion for example.~In addition, the doctor will prescribe anti-inflammatory drugs to ease the pain and physiotherapy to establish proprioception, muscle strength, joint range and dynamic postural balance of the sprain.
Study NCT04999254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: Medical treatment will be based on functional treatment and the doctor will prescribe the RICE protocol. For this, the patient will have to :~* place an ice pack on the sprain~* apply sports rest for three weeks~* compress the sprain with a compression stocking when standing in order to prevent phlebitis. In addition, to avoid this complication, the doctor will prescribe an anticoagulant.~* raise the foot with crutches during the day~* elevate the foot at night or when doing an activity in a sitting position, using a cushion for example.~In addition, the doctor will prescribe anti-inflammatory drugs to ease the pain and physiotherapy to establish proprioception, muscle strength, joint range and dynamic postural balance of the sprain.
Study NCT04999254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic treatment
Description: Each patient will be treated as a whole and within a time limit of 45 minutes. The consultation will start with a medical history followed by medical tests. Then, the osteopath will perform osteopathic tests and manual treatment.
Study NCT04739371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, Regular, Human
Description: The spray will last a few seconds and then the participant will be asked to sniff to aid the drug into the nose. The device (i.e. ViaNase) is an atomizer that uses its patented technology that turns the liquid into a fine mist of droplets to facilitate the drug along the nose to brain pathway. Each nostril will receive this administration 2 times for a total of 40 IUs or 0.4 mL of liquid.
Study NCT05177094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally
Study NCT05177094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally